TI
LTRN icon

tru Independence’s Lantern Pharma LTRN Stock Holding History

tru Independence’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-500
Closed -$6 – 623
2020
Q2 		$6 Buy
+500
New +$6.46K ﹤0.01% 680

Other funds holding LTRN

ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCG
Rock Creek Group Washington, District of Columbia $988M AUM 8.89% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CCM
Chiron Capital Management Tallahassee, Florida $111M AUM
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

tru Independence's LTRN Position: Q3 2020 in Review

tru Independence sold out of Lantern Pharma (LTRN) in Q3 2020, closing a stake of 500 shares — an estimated $6 sold.

tru Independence first reported a position in LTRN in Q2 2020 and held it in 1 quarter. The position peaked at $6 in Q2 2020. 12 funds tracked by Wall St. Rank hold LTRN as of Q3 2020.

  • tru Independence reported no remaining Lantern Pharma position as of Q3 2020 after selling out during the quarter.
  • tru Independence sold 500 Lantern Pharma shares in Q3 2020, an estimated $6.
  • tru Independence first reported a position in Lantern Pharma in Q2 2020 and held it in 1 quarter.
  • tru Independence's Lantern Pharma position peaked at $6 in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Lantern Pharma as of Q3 2020.

Based on tru Independence's 13F filing for Q3 2020, filed 19 Nov 2020.